Skip to main content
Home > SciBX > Translational Notes

Chronological Index of SciBX: The Science-Business eXchange: Translational Notes

SciBX: The Science-Business eXchange Current Issue
  • Oxford goes big (data)

    University of Oxford is bringing big data to translational research. The university, the U.K. government and a philanthropist are infusing up to L90 million ($138.3 million) to set up a new hub that will use large-scale…

    Published on 5/23/2013
  • Table 1: Sage Bionetworks-DREAM Project spring 2013 challenges

    Translational Notes: DREAM team Table 1. Sage Bionetworks-DREAM Project spring 2013 challenges. Sage Bionetworks and The DREAM Project have announced four open-innovation computational challenges that tackle issues …

    Published on 5/9/2013
  • DREAM team

    The DREAM Project has teamed up with Sage Bionetworks and announced four open challenges in computational biology that tackle issues relevant to drug discovery and development. The publication of results from their …

    Published on 5/9/2013
  • Structural guidance for malaria and TB

    The Structural Genomics Consortium, with grant support from the Bill & Melinda Gates Foundation, is spearheading a project to develop pharma-quality medicinal chemistry capabilities in malaria and tuberculosis. The plan…

    Published on 5/9/2013
  • Multiple myeloma partners

    The U.K.-based Institute of Cancer Research and Cancer Research Technology Ltd. are collaborating with Janssen to target an undisclosed step in the unfolded protein response in multiple myeloma. Previous results from …

    Published on 4/18/2013
  • GSK's electric frontier

    GlaxoSmithKline today launched an academic partnering program and a $1 million cash prize to spark technology development in the new field of electroceuticals. The pharma's goal is to manipulate nerve impulses to treat …

    Published on 4/11/2013
  • Table 1: GSK's Discovery Partnerships with Academia (DPAc) deals

    Translational Notes: GSK goes deep with DPAc Table 1. GSK's Discovery Partnerships with Academia (DPAc) deals. Since launching the DPAc program in 2010, GlaxoSmithKline plc has partnered with nine academic teams to …

    Published on 3/14/2013
  • GSK goes deep with DPAc

    GSK's Discovery Partnerships with Academia (DPAc) program is helping the pharma cast a wide net for early stage therapeutics beyond its core areas. So far this year, GSK has struck discovery deals with Vanderbilt …

    Published on 3/14/2013
  • Table 1: Founders and awardees

    Funding breakthroughs Table 1. Founders and awardees. Founders Title(s) Science background Sergey Brin Cofounder of Google Inc. Bachelor's degree in mathematics and computer science from the University of …

    Published on 3/7/2013
  • Funding breakthroughs

    Although everyone agrees that the $33 million in prize money from the Breakthrough Prize in Life Sciences Foundation went to 11 deserving scientists, it is still up for debate whether, in an age of austerity, there are …

    Published on 3/7/2013
  • Big brain science

    The Brain Activity Map has been compared to the Human Genome Project; however, unlike mapping the relatively well-defined genome, the plan to visualize the brain's complete wiring scheme faces severe technical …

    Published on 3/7/2013
  • Translational globetrotting

    Six like-minded translational research centers have partnered to help speed the commercialization of academic research. The group, dubbed the Global Alliance of Leading Drug Discovery and Development Centres, comprises …

    Published on 1/31/2013
  • Table 1: IMI's fourth call

    IMI's collaborative chemistry Table 1. IMI's fourth call. The fourth set of projects launched by the Innovative Medicines Initiative (IMI) comprise seven projects that are a joint effort of the European Commission …

    Published on 1/24/2013
  • IMI's collaborative chemistry

    Europe's Innovative Medicines Initiative has launched seven new public-private partnerships with a total budget of EUR237 million. In contrast to many of the organization's prior disease-focused projects, three of the …

    Published on 1/24/2013
  • DUX4 partnership

    Fred Hutchinson Cancer Research Center researchers have identified a mutation of double homeobox 4 that could be targeted in facioscapulohumeral muscular dystrophy. The team has partnered with GlaxoSmithKline to develop…

    Published on 1/10/2013
  • Table 1: MRC technology deals

    MRC Technology extends reach Table 1. MRC technology deals. Year Indication Collaborator Deal Therapeutic modality 2012 Undisclosed Shanghai Institute of Biochemistry and Cell Biology (SIBCB), part of the …

    Published on 12/20/2012
  • Table 2: Centre for Therapeutics Discovery

    MRC Technology extends reach Table 2. Centre for Therapeutics Discovery. Target Project Stage of ­development Collaborator Undisclosed Undisclosed Hit to lead Undisclosed Melanocortin 3 receptor (MC3R) MC3R…

    Published on 12/20/2012
  • MRC Technology extends reach

    The U.K.'s Medical Research Council is taking its search for targets to Asia. The MRC's commercialization arm, MRC Technology, has announced a deal with the Shanghai Institute of Biochemistry and Cell Biology.

    Published on 12/20/2012
  • Quebec's research resurrection

    A shuttered AstraZeneca research center in Montreal has reemerged as Neomed, a public-private partnership between AstraZeneca, Pfizer and the government of Quebec. The institute will continue to develop AstraZeneca's …

    Published on 12/13/2012
  • Genomics in the Big Apple

    The New York Genome Center launched its translational research unit last week with the appointment of Robert Darnell as president and scientific director. Darnell will oversee the development of internal research …

    Published on 12/6/2012
  • Figure 1: Antibiotic approvals over the last three decades in five-year increments

    Rediscovering ­antibiotics Figure 1. Antibiotic approvals over the last three decades in five-year increments. In 1983-1987 the FDA approved 16 new systemic antibiotics, but since that time antibiotic approvals have …

    Published on 11/29/2012
  • Rediscovering antibiotics

    The implementation of the Generating Antibiotic Incentives Now (GAIN) Act and other recent efforts to speed antibiotic development will only be successful if they encourage new chemical approaches that address the …

    Published on 11/29/2012
  • Animal instincts

    A workshop convened by the NINDS has proposed a set of standards for designing and reporting on animal studies. The challenges will be to implement the standards throughout the research community and determine which …

    Published on 11/8/2012
  • Table 1: CPRIT's commercial portfolio

    Translational Notes: Mess with Texas Table 1. CPRIT's commercial portfolio. The Cancer Prevention & Research Institute of Texas (CPRIT) has issued about $760 million in funding to academic researchers, community …

    Published on 11/1/2012
  • From bedside to bench

    The recently announced oncology R&D collaboration between Sanofi and Massachusetts General Hospital takes a different tack than most translational research partnerships by starting with insights gleaned from the bedside…

    Published on 11/1/2012

< Previous   1  2  3  4  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993

Log In


Forgot password  |  Forgot Login


If you are a subscriber, but have forgotten or never received a password, please click above to receive a new one.

SciBX: Science-Business eXchange

BioCentury's weekly translational science journal, published in collaboration with Nature Publishing Group:

  • Selects from hundreds of scientific papers published each week to identify early opportunities for investment, alliances and partnerships
  • Reports on the most commercially relevant developments